Hennion & Walsh Asset Management Inc. Acquires 11,304 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Hennion & Walsh Asset Management Inc. lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 17.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,610 shares of the specialty pharmaceutical company's stock after purchasing an additional 11,304 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.14% of Supernus Pharmaceuticals worth $2,542,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Woodline Partners LP raised its holdings in shares of Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock valued at $15,326,000 after buying an additional 235,257 shares during the last quarter. BNP Paribas Financial Markets raised its position in Supernus Pharmaceuticals by 248.0% in the 4th quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after purchasing an additional 208,552 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $6,847,000. Great Lakes Advisors LLC bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $6,131,000. Finally, D. E. Shaw & Co. Inc. lifted its holdings in Supernus Pharmaceuticals by 33.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock valued at $19,731,000 after buying an additional 136,870 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SUPN shares. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, May 16th.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock traded up $0.04 during midday trading on Thursday, reaching $32.34. 296,078 shares of the company's stock were exchanged, compared to its average volume of 481,219. The stock's 50-day simple moving average is $31.93 and its 200 day simple moving average is $34.51. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 30.22 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.